2024
"SafetyNet": Evaluation of a Recovery Coach and Paramedic Intervention Following Naloxone Resuscitation From an Opioid Overdose.
Joseph D, Brokowski C, D'Onofrio G, Bogucki S, McGovern J, Allen R, Dziura J, Cone D, Pantalon M. "SafetyNet": Evaluation of a Recovery Coach and Paramedic Intervention Following Naloxone Resuscitation From an Opioid Overdose. Substance Use & Addiction Journal 2024, 29767342241266412. PMID: 39171791, DOI: 10.1177/29767342241266412.Peer-Reviewed Original ResearchOverdose eventsRecovery coachesOpioid overdoseFollow-up encountersReducing illicit drug useFifty-five participantsIllicit drug useParamedic interventionsTrained paramedicsPeer recoveryFollow-upHealth educationOpioid use disorderSample size estimationParamedicsOpioid-positive urine testsPositive urine toxicology screenMOUD engagementMedical concernsMOUDUrine toxicology screenDrug useParticipantsPositive urine testIntervention
2013
Nonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion?
Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti‐inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: The egg of columbus or another illusion? Hepatology 2013, 58: 819-821. PMID: 23703812, DOI: 10.1002/hep.26498.Peer-Reviewed Original Research
2009
A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Liu H, Chen L, Nicoletti M, Stork L, Bostrom B, Neglia JP. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009, 114: 1746-1752. PMID: 19546477, PMCID: PMC2738566, DOI: 10.1182/blood-2008-12-186502.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaDexamethasone groupLymphoblastic leukemiaNeurocognitive functioningHigher event-free survival rateEvent-free survival rateCentral nervous system penetrationLong-term cognitive functioningPsychotropic drug usePrevious clinical trialsWorse neurocognitive functioningCorticosteroid RandomizationNeurocognitive toxicityPrednisone groupNeurologic complicationsClinical trialsSignificant overall differenceSurvival rateDrug useYounger ageWorse functioningOlder ageDiagnosisMultisite study